Floatz logo

Velaglucerase Alfa

Gaucher Disease Type 3

Baylor Research Instituteprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Gaucher Disease Type 3 cohort.

Asset / SponsorPhaseRating
Cerezyme
Genzyme, a Sanofi Company
Phase 2CCC
Eliglustat
Genzyme, a Sanofi Company
Phase 2CCC
Venglustat
Genzyme, a Sanofi Company
Phase 2CCC
Vgn-R08B
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2CCC

Same molecule, other indications

Velaglucerase Alfa is also rated in:

Gaucher diseaseDormant
A
Indicative ·
83 / 100
View asset →
Gaucher Disease, Type 1Dormant
A
Indicative ·
81 / 100
View asset →
diseaseDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →